GenSight Biologics SA's total assets for Q4 2024 were €10.76M, a decrease of -28.23% from the previous quarter. DE:G49N total liabilities were €37.68M for the fiscal quarter, a -5.38% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.